These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 21555689)

  • 21. Aromatase inhibitors in advanced breast cancer.
    Mouridsen HT
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):3-8. PubMed ID: 15719595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
    Freedman OC; Amir E; Hanna W; Kahn H; O'Malley F; Dranitsaris G; Cole DE; Verma S; Folkerd E; Dowsett M; Clemons M
    Breast Cancer Res Treat; 2010 Jan; 119(1):155-61. PubMed ID: 19731013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO).
    Gennatas C; Michalaki V; Carvounis E; Psychogios J; Poulakaki N; Katsiamis G; Voros D; Kouloulias V; Mouratidou D; Tsavaris N
    Tumori; 2006; 92(1):13-7. PubMed ID: 16683378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
    Murray J; Young OE; Renshaw L; White S; Williams L; Evans DB; Thomas JS; Dowsett M; Dixon JM
    Breast Cancer Res Treat; 2009 Apr; 114(3):495-501. PubMed ID: 18438705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
    Krainick-Strobel UE; Lichtenegger W; Wallwiener D; Tulusan AH; Jänicke F; Bastert G; Kiesel L; Wackwitz B; Paepke S
    BMC Cancer; 2008 Feb; 8():62. PubMed ID: 18302747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary hormone treatment in postmenopausal women with breast cancer.
    Maciá Escalante S; Pons Sanz V; Rodríguez Lescure A; Ballester Navarro I; Carrato Mena A
    Clin Transl Oncol; 2006 May; 8(5):372-4. PubMed ID: 16760014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
    Riemsma R; Forbes CA; Kessels A; Lykopoulos K; Amonkar MM; Rea DW; Kleijnen J
    Breast Cancer Res Treat; 2010 Aug; 123(1):9-24. PubMed ID: 20535542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
    Madeira M; Mattar A; Logullo AF; Soares FA; Gebrim LH
    BMC Cancer; 2013 Sep; 13():425. PubMed ID: 24047421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aromatase inhibitors in early breast cancer therapy.
    Smith IE
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):9-14. PubMed ID: 15719596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
    Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
    Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular response to aromatase inhibitor treatment in primary breast cancer.
    Mackay A; Urruticoechea A; Dixon JM; Dexter T; Fenwick K; Ashworth A; Drury S; Larionov A; Young O; White S; Miller WR; Evans DB; Dowsett M
    Breast Cancer Res; 2007; 9(3):R37. PubMed ID: 17555561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
    Geisler J
    Br J Cancer; 2011 Mar; 104(7):1059-66. PubMed ID: 21364577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS
    Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
    Glück S; Gorouhi F
    Am J Health Syst Pharm; 2011 Sep; 68(18):1699-706. PubMed ID: 21880884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Letrozole in the neoadjuvant setting: the P024 trial.
    Ellis MJ; Ma C
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):33-43. PubMed ID: 17912634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
    Arnedos M; Drury S; Afentakis M; A'Hern R; Hills M; Salter J; Smith IE; Reis-Filho JS; Dowsett M
    Ann Oncol; 2014 Mar; 25(3):605-610. PubMed ID: 24525703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
    Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
    J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.